EUCTR2017-004630-29-IT进行中（未招募）1 期
A phase II, open label, multicenter trial of Venetoclax (ABT-199/GDC-0199) as single agent in patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal T-cell lymphomas of T-follicular helper origin (TFH). - FIL_VERT
FONDAZIONE ITALIANA LINFOMI ONLUS0 个研究点目标入组 35 人开始时间: 2021年6月14日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically documented diagnosis of BCL-2 positive PTCL-NOS, AITL, TFH as defined in the 2016 edition of the World Health Organization (WHO) classification. Only patients with percentage of BCL-2 positive tu-mor cells >= 25% in the relapse biopsy, if available, or otherwise in the ini-tial biopsy, will be included onto the study;
- •Age >= 18 years
- •Relapsed or refractory to at least one previous standard line of treatment
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2
- •At least one site of measurable nodal or extranodal disease at baseline >= 2.0 cm in the longest transverse diameter as determined by CT scan (MRI is allowed only if CT scan cannot be performed). Note: Patients with only bone marrow involvement are eligible
- •Adequate hematological counts defined as follows:
- •- Absolute Neutrophil count (ANC) > 1.0 x 10^9/L unless due to bone marrow involvement by lymphoma
- •- Platelet count >= 50.000/mm^3 unless due to bone marrow involvement by lymphoma
- •Adequate renal function defined as follows:
- •- Creatinine clearance >= 30 mL/min
- •Adequate hepatic function per local laboratory reference range as follows:
- •- Aspartate transaminase (AST) and alanine transaminase (ALT) <= 3.0 x ULN
- •- Bilirubin <=1.5 x ULN (unless bilirubin rise is due to Gilbert’s syn-drome or of non-hepatic origin)
- •Subject understands and voluntarily signs an informed consent form ap-proved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific proce-dures
- •Subject must be able to adhere to the study visit schedule and other pro-tocol requirements
- •Subject must be able to swallow capsules or tablets
- •Life expectancy >= 3 months
- •Women must be:
- •- postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)
- •- surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
- •- completely abstinent (periodic abstinence from intercourse is not permit-ted) or if sexually active, be practicing a highly effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e.g.: condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth con-trol measures for at least 1 month after terminating treatment.
- •- women of childbearing potential must have a negative pregnancy test at screening
- •Men must agree to use an acceptable method of contraception (fort them-selves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 1 month after receiving the last dose of study drug.
- •Male even if surgically sterilized (i.e., status postvasectomy) must agree to 1 of the following:
- •- practice effective barrier contraception during the entire study treatment period and through 1 months after the last dose of study drug, or
- •- agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the femal
排除标准
- •Histological diagnosis different from BCL-2 positive PTCL-NOS, AITL, and TFH
- •Allogeneic or autologous stem cell transplant within 6 months prior to the informed consent signature
- •Treatment with any of the following within 7 days prior to the first dose of study drug:
- •- steroid therapy for anti-neoplastic intent
- •- moderate or strong cytochrome P450 3A (CYP3A) inhibitors (see Ap-pendix C for examples)
- •- moderate or strong CYP3A inducers (see Appendix C for examples)
- •Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, investigational therapy, including targeted small molecule agents within 14 days prior to the first dose of study drug
- •History of CNS involvement by lymphoma
- •Administration or consumption of any of the following within 3 days prior to the first dose of study drug:
- •- grapefruit or grapefruit products
- •- Seville oranges (including marmalade containing Seville oranges)
- •- star fruit
- •Previous treatment with a BCL-2 family protein inhibitor
- •Subject is known to be positive for HIV (HIV testing is not required)
- •Cardiovascular disease (NYHA class >=2)
- •Creatinine Clearance < 30 mL/min
- •Significant history of neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent.
- •Any history of other active malignancies within 3 years prior to study entry, with the exception of adequately treated in situ carcinoma of the cervix uterine, basal cell carcinoma of the skin or localized squamous cell carci-noma of the skin, previous malignancy confined and surgically resected with curative intent.
- •Subject who has malabsorption syndrome or other condition which pre-cludes enteral route of administration.
- •Evidence of other clinically significant uncontrolled condition(s) including, but not limited to uncontrolled and/or active systemic infection (viral, bacte-rial or fungal)
- •Active HBV positive hepatitis
- •-The following categories of patients HBV positive but with non evidence of active hepatitis may be considered for the study:
- •- HBsAg positive with HBV DNA < 2000 UI/ml (inactive carriers); HBV DNA > 2000 UI/ml is criteria of exclusion
- •- HBsAg negative but HBsAb positive
- •- HBsAg negative but HBcAb positive
- •- Patients HBsAg positive with HBV DNA < 2000 UI/ml and HBsAg nega-tive but HBcAb positive will be eligible for the study only if they accept to receive prophylactic Lamivudine 100 mg/daily for all the period of treat-ment and at least for 12 months after the end of therapy. Treatment with ABT-199 should be stopped in case of hepatitis reactivation.
- •Active HCV positive hepatitis
- •If female, the patient is pregnant or breast-feeding.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104Multiple MyelomaCTIS2023-505659-27-00AbbVie Deutschland GmbH & Co. KG127
进行中（未招募）
1 期
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2019-004340-30-HUAbbVie Deutschland GmbH & Co. KG120
进行中（未招募）
不适用
An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancerChemorefractory metastatic adenocarcinoma of stomach, esophagogastric junction and lower esophagus (Barrett carcinoma)MedDRA version: 8.1Level: LLTClassification code 10017758Term: Gastric cancerEUCTR2006-000476-33-DEJohannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik50
进行中（未招募）
1 期
A clinical trial of nebulised recombinant tissue plasminogen activator (rtPA) in patients with COVID-19 Acute Respiratory Distress Syndrome to decrease the duration of ventilatory support and mortality: A pilot study (the PACA trial)Acute respiratory distress syndrome (ARDS) caused by COVID-19EUCTR2020-001640-26-GBniversity College London36
进行中（未招募）
1 期
A MULTICENTER TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL RECURRENT CANCER PATIENTSOvarian, fallopian tube or primary peritoneal recurrent cancerMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10038604Term: Reproductive system and breast disordersSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2018-003736-77-DEIstituto di Ricerche Farmacologiche Mario Negri IRCCS105